KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2021 - 2025)

Alnylam Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at $52.3 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $52.3 million; the TTM value through Dec 2025 reached $1.2 billion, up 213.48%, while the annual FY2025 figure was $1.2 billion, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $52.3 million in Q4 2025 per ALNY's latest filing, down from $1.1 billion in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.1 billion in Q3 2025 to a low of -$1.5 billion in Q4 2022.
  • Average Long-Term Debt Repayments over 3 years is $34.5 million, with a median of $276.2 million recorded in 2021.
  • The largest YoY upside for Long-Term Debt Repayments was 404.84% in 2022 against a maximum downside of 404.84% in 2022.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $500.0 million in 2021, then tumbled by 404.84% to -$1.5 billion in 2022, then surged by 103.43% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Long-Term Debt Repayments are $52.3 million (Q4 2025), $1.1 billion (Q3 2025), and -$1.5 billion (Q4 2022).